Gov. J.B. Pritzker announced Wednesday that Illinois will expand the list of people eligible for COVID-19 vaccinations in Phase 1B of its rollout.
The state believes that this increased eligibility beginning Feb. 25, will allow people with “a high-risk medical condition” or comorbidity to be vaccinated. The list includes those with cancer, diabetes, obesity, women who are pregnant, and those with several other conditions.
“In light of a steadily increasing federal vaccine supply, Illinois is making plans to expand Phase 1B eligibility on February 25 to people who have comorbidities and underlying conditions as defined by the CDC,” the governor’s office said in a release. “In addition, Illinois will also prioritize individuals with disabilities.”
The list of qualifying high-risk medical conditions (which is subject to change) includes:
You May Also Like
- Cancer
- Chronic Kidney Disease
- COPD (Chronic Obstructive Pulmonary Disease)
- Diabetes
- Heart Condition
- Immunocompromised State from a Solid Organ Transplant
- Obesity
- Pregnancy
- Pulmonary Disease
- Sickle Cell Disease
“Those who are under 65 and live with comorbidities, such as cancer survivors or those living with heart disease, have an elevated risk of serious complications or death if they contract COVID-19,” Pritzker said in a statement. “Illinois is moving forward in accordance with guidance from the CDC to expand our eligible population as supply allows, getting us closer to the point when the vaccine is widely available to all who want it. In the meantime, I encourage all Illinoisans to wear our masks and follow the mitigations so that more of our neighbors are healthy and alive when it’s their turn in the vaccination line.”
The expanded eligibility applies to persons age 16 and older who were not covered in previous eligibility categories, the state said, adding that it plans to work with local health departments and other providers as eligibility increases.
According to Illinois and U.S. medical experts, pregnant women were excluded from trials for the vaccine, because of minimal information on the vaccines’ safety for that group.
